Shenzhen Neptunus Bioengineering Co Ltd (000078) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has a cash flow conversion efficiency ratio of -0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-16.37 Million ≈ $-2.40 Million USD) by net assets (CN¥2.85 Billion ≈ $416.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 000078 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Shenzhen Neptunus Bioengineering Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rio2 Ltd
V:RIO
|
-0.051x |
|
Fireweed Zinc Ltd
V:FWZ
|
-0.677x |
|
Legacy Housing Corp
NASDAQ:LEGH
|
0.013x |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
-0.709x |
|
Standard Chartered PLC
LSE:STAN
|
-0.003x |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
0.058x |
|
Tilray Inc
NASDAQ:TLRY
|
-0.015x |
|
ChongQing Zhengchuan Pharmaceutical Packaging Co Ltd
SHG:603976
|
0.038x |
Annual Cash Flow Conversion Efficiency for Shenzhen Neptunus Bioengineering Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Neptunus Bioengineering Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see 000078 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.18 Billion ≈ $318.49 Million |
CN¥104.39 Million ≈ $15.28 Million |
0.048x | +244.96% |
| 2024-12-31 | CN¥2.84 Billion ≈ $416.13 Million |
CN¥39.54 Million ≈ $5.79 Million |
0.014x | +114.30% |
| 2023-12-31 | CN¥4.22 Billion ≈ $617.14 Million |
CN¥-410.19 Million ≈ $-60.02 Million |
-0.097x | -823.85% |
| 2022-12-31 | CN¥6.11 Billion ≈ $894.15 Million |
CN¥-64.33 Million ≈ $-9.41 Million |
-0.011x | -108.88% |
| 2021-12-31 | CN¥7.31 Billion ≈ $1.07 Billion |
CN¥866.12 Million ≈ $126.74 Million |
0.119x | -46.22% |
| 2020-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
CN¥1.65 Billion ≈ $241.53 Million |
0.220x | -23.74% |
| 2019-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
CN¥2.27 Billion ≈ $331.97 Million |
0.289x | +282.22% |
| 2018-12-31 | CN¥7.16 Billion ≈ $1.05 Billion |
CN¥-1.14 Billion ≈ $-166.11 Million |
-0.159x | +57.83% |
| 2017-12-31 | CN¥6.47 Billion ≈ $946.76 Million |
CN¥-2.43 Billion ≈ $-356.01 Million |
-0.376x | -47.65% |
| 2016-12-31 | CN¥5.88 Billion ≈ $860.13 Million |
CN¥-1.50 Billion ≈ $-219.06 Million |
-0.255x | -703.04% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.60 Million |
CN¥90.51 Million ≈ $13.24 Million |
0.042x | +164.08% |
| 2014-12-31 | CN¥1.78 Billion ≈ $260.85 Million |
CN¥-117.48 Million ≈ $-17.19 Million |
-0.066x | -1.10% |
| 2013-12-31 | CN¥1.89 Billion ≈ $276.27 Million |
CN¥-123.07 Million ≈ $-18.01 Million |
-0.065x | +15.69% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.67 Million |
CN¥-81.73 Million ≈ $-11.96 Million |
-0.077x | +60.55% |
| 2011-12-31 | CN¥971.04 Million ≈ $142.09 Million |
CN¥-190.33 Million ≈ $-27.85 Million |
-0.196x | -531.98% |
| 2010-12-31 | CN¥902.62 Million ≈ $132.08 Million |
CN¥40.96 Million ≈ $5.99 Million |
0.045x | -84.77% |
| 2009-12-31 | CN¥692.59 Million ≈ $101.35 Million |
CN¥206.34 Million ≈ $30.19 Million |
0.298x | +13.26% |
| 2008-12-31 | CN¥780.79 Million ≈ $114.25 Million |
CN¥205.39 Million ≈ $30.05 Million |
0.263x | +369.89% |
| 2007-12-31 | CN¥903.62 Million ≈ $132.23 Million |
CN¥50.59 Million ≈ $7.40 Million |
0.056x | -10.00% |
| 2006-12-31 | CN¥868.76 Million ≈ $127.13 Million |
CN¥54.04 Million ≈ $7.91 Million |
0.062x | +39.82% |
| 2005-12-31 | CN¥805.26 Million ≈ $117.83 Million |
CN¥35.82 Million ≈ $5.24 Million |
0.044x | +205.31% |
| 2004-12-31 | CN¥1.45 Billion ≈ $212.47 Million |
CN¥-61.34 Million ≈ $-8.98 Million |
-0.042x | -114.41% |
| 2003-12-31 | CN¥1.44 Billion ≈ $211.22 Million |
CN¥-28.44 Million ≈ $-4.16 Million |
-0.020x | +63.65% |
| 2002-12-31 | CN¥2.06 Billion ≈ $301.91 Million |
CN¥-111.83 Million ≈ $-16.36 Million |
-0.054x | -29.21% |
| 2001-12-31 | CN¥1.97 Billion ≈ $288.97 Million |
CN¥-82.84 Million ≈ $-12.12 Million |
-0.042x | +90.83% |
| 2000-12-31 | CN¥238.75 Million ≈ $34.94 Million |
CN¥-109.25 Million ≈ $-15.99 Million |
-0.458x | -367.67% |
| 1999-12-31 | CN¥205.69 Million ≈ $30.10 Million |
CN¥-20.13 Million ≈ $-2.95 Million |
-0.098x | +54.56% |
| 1998-12-31 | CN¥177.08 Million ≈ $25.91 Million |
CN¥-38.13 Million ≈ $-5.58 Million |
-0.215x | -- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more